✦ LIBER ✦

P55 Prognostic significance of bcl-2 expression in stage III breast cancer patients who received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

✍ Scribed by S.-A. Im; K.-H. Lee; D.-Y. Oh; W. Han; J.H. Kim; D.-W. Kim; T.-Y. Kim; I.A. Park; D.-Y. Noh; Y.-J. Bang

Book ID: 114315973
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 46 KB
Volume: 16
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(07)70120-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic significance of bcl-2 express

Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy

✍ Kyung-Hun Lee; Seock-Ah Im; Do-Youn Oh; Se-Hoon Lee; Eui Kyu Chie; Wonshik Han; 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 282 KB

Biweekly docetaxel and gemcitabine as ne

Biweekly docetaxel and gemcitabine as neoadjuvant chemotherapy followed by adjuvant doxorubicin and cyclophosphamide therapy in stage II and III breast cancer patients: results of a phase II study

✍ L. G. Estévez; P. Sánchez-Rovira; M. Dómine; A. León; I. Calvo; A. Jaén; V. Casa 📂 Article 📅 2007 🏛 Springer Milan 🌐 Spanish ⚖ 80 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views

Seven-Year Follow-Up Assessment of Cardi

Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

✍ Zibelman, M.; Goldstein, L.J. 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 54 KB